Skip to Content


In the US, Ibrance (palbociclib systemic) is a member of the drug class CDK 4/6 inhibitors and is used to treat Breast Cancer, Breast Cancer - Male, Breast Cancer - Metastatic and Liposarcoma.

US matches:

UK matches:

Ingredient matches for Ibrance


Palbociclib is reported as an ingredient of Ibrance in the following countries:

  • Argentina
  • Australia
  • Belgium
  • Bosnia & Herzegowina
  • Canada
  • Central African Republic
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Lithuania
  • Netherlands
  • New Zealand
  • Norway
  • Romania
  • Slovakia
  • Slovenia
  • Sweden
  • United Kingdom
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.